Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept NSAID Sparing in Axial Spondyloarthritis
NCT01298531Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2011
- Primary completion
- Jan 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Etanercept with Placebo -> Etanercept (2 arms). Primary endpoint: Change From Baseline in Non Steroidal Anti Inflammatory Drug (NSAID) Assessment of the SpondyloArthritis International Society (ASAS) Score at 8 weeks. Started May 2011; status: completed.
02
Drugs
etanercept
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT01298531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298531.